VICTOZA
Drug
Novo Nordisk AS
Total Payments
$34,732
Transactions
14
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $34,732 | 14 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $34,732 | 14 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NN2211-4232 | Novo Nordisk AS | $34,724 | 0 |
| NN2211-4315 | Novo Nordisk AS | $8.00 | 0 |
Top Doctors Receiving Payments for VICTOZA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Jacksonville, FL | $34,732 | 14 |
Ad
Manufacturing Companies
- Novo Nordisk AS $34,732
Product Information
- Type Drug
- Total Payments $34,732
- Total Doctors 0
- Transactions 14
About VICTOZA
VICTOZA is a drug associated with $34,732 in payments to 0 healthcare providers, recorded across 14 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk AS.
Payment data is available from 2019 to 2019. In 2019, $34,732 was paid across 14 transactions to 0 doctors.
The most common payment nature for VICTOZA is "Unspecified" ($34,732, 100.0% of total).
VICTOZA is associated with 2 research studies, including "NN2211-4232" ($34,724).